10-Q
Quarterly Report
AIM IMMUNOTECH INC.
AIM
NYSE
CIK: 946644
File #: 001-27072
Balance Sheet
30 line items · 2 periods
XBRL
| Item | Sep 30, 2023 | Dec 31, 2022 |
|---|---|---|
ASSETS | ||
Current assets: | ||
Cash and Cash Equivalents | 15,264,000 | 27,053,000 |
Cash and Cash Equivalents | 7,167,000 | 7,137,000 |
Accounts Receivable | 48,000 | 1,676,000 |
Other Non-Operating Current Assets | 263,000 | 455,000 |
Total current assets | 22,742,000 | 36,321,000 |
Property, Plant and Equipment | 136,000 | 195,000 |
Operating Lease Right-of-Use Asset | 727,000 | 829,000 |
Intangible Assets | 2,154,000 | 1,941,000 |
Other Non-Operating Non-Current Assets | 2,102,000 | 1,202,000 |
Total assets | 27,861,000 | 40,488,000 |
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
Current liabilities: | ||
Accounts Payable | 2,788,000 | 377,000 |
Other Current Liabilities | 1,721,000 | 806,000 |
Operating Lease Liability, Current | 207,000 | 178,000 |
Total current liabilities | 4,716,000 | 1,361,000 |
Long-term liabilities: | ||
Operating Lease Liability, Non-Current | 543,000 | 659,000 |
Stockholders’ equity: | ||
Series B Convertible Preferred Stock | 690,000 | 696,000 |
Total Stockholders' Equity | 48,000 | 48,000 |
Total Stockholders' Equity | 418,796,000 | 418,270,000 |
Total Stockholders' Equity | (396,932,000) | (380,546,000) |
Total stockholders’ equity | 22,602,000 | 38,468,000 |
Common Stock | 48,000 | 48,000 |
Additional Paid-in Capital | 418,796,000 | 418,270,000 |
Retained Earnings | (396,932,000) | (380,546,000) |
Total liabilities and stockholders’ equity | 27,861,000 | 40,488,000 |